Pipeline Overview

Pipeline Overview

Developing a broad pipeline of novel immunotherapeutic antibodies harnessing the innate & adaptive immune responses

Our initial focus is on developing novel IO therapeutics targeting BTN(L)s to treat a range of solid tumors and hematologic cancers.  Our programs were initially centered around the powerful mechanisms of action of γ9δ2 T cells, however, as our understanding of the BTN(L) biology has evolved we have utilized this knowledge to generate intellectual property around targeting other immune cell populations to create a diversified IO pipeline.

In parallel to advancing our IO programs, ImCheck is designing inhibitory mAbs that can diminish the dysfunctional immune system activation in autoimmune diseases.  The company will remain strategic in our selection of programs to advance in-house and those we will consider for partnering.

A company that delivers innovation

Prof. René HOET, PhD

Chief Scientific Officer

A company that delivers innovation

ImCheck has made rapid advances with first-in-class antibodies that are moving towards the clinic, as well as a wealth of exciting antibody discovery programs addressing novel targets in IO and auto-immunity. I am delighted to put my over 20 years’ experience in antibody discovery and development to bring these molecules to patients in medical need.